| 1679 |
National Cancer Institute |
Html |
en |
Communication in Cancer Care (PDQ®)–Patient Version |
It is important to talk to your doctor about your cancer diagnosis, goals of treatment, plan of care, and what to expect over time. Learn how good communication between patients, families, caregivers and doctors can improve the patient's quality of life in this expert-reviewed summary. |
| cancer treatment | 0.389842 |
| bad news | 0.386292 |
| questions | 0.399361 |
| PDQ cancer information | 0.624305 |
| health care team | 0.981737 |
| clinical trials | 0.514782 |
| Pediatric Supportive Care | 0.404638 |
| communication | 0.486074 |
| cancer information summary | 0.515585 |
| clinical trial | 0.495706 |
| family members | 0.426143 |
| cancer care | 0.778281 |
| breast cancer prevention | 0.399685 |
| PDQ summaries | 0.394467 |
| patients | 0.573309 |
| cancer patients | 0.414288 |
| team share information | 0.427277 |
| latest published information | 0.403211 |
| NCI’s PDQ | 0.394236 |
| PDQ summary Family | 0.458483 |
| NCI PDQ cancer | 0.456705 |
| supportive care | 0.443184 |
| treatment | 0.599848 |
| family caregivers | 0.667411 |
|
| cancer prevention | 0.402033 |
| Cancer Information Service | 0.427003 |
| Explain medical information | 0.409499 |
| PDQ Supportive | 0.391221 |
| patient | 0.679815 |
| PDQ Communication | 0.403164 |
| treatment clinical trials | 0.401111 |
| National Cancer Institute | 0.597923 |
| decisions | 0.454448 |
| PDQ documents | 0.390179 |
| Palliative Care Editorial | 0.462952 |
| medical information | 0.462988 |
| new treatment | 0.398754 |
| good communication | 0.425774 |
| Cancer Care page | 0.429643 |
| PDQ database | 0.392979 |
| Care Editorial Board | 0.465833 |
| PDQ summary | 0.483184 |
| doctor | 0.450453 |
| cancer clinical trials | 0.415988 |
| cancer information summaries | 0.432334 |
| comprehensive cancer information | 0.43347 |
| cancer patient | 0.392432 |
| cancer | 0.840307 |
|
CLICK HERE |
| 1711 |
National Cancer Institute |
Html |
en |
Breast Cancer Risk in American Women |
A fact sheet that provides statistics about a woman’s risk of developing breast cancer and information about breast cancer risk factors. |
| current incidence rates | 0.345094 |
| Physical activity level | 0.337892 |
| woman’s risk | 0.354657 |
| certain genes | 0.34342 |
| breast cancer increases | 0.425903 |
| Certain breast changes | 0.409974 |
| Mammographic breast density | 0.411613 |
| Indian/Alaska Native women | 0.346578 |
| breast biopsies | 0.390019 |
| Breast Cancer Risk | 0.442755 |
| following risk factors | 0.34953 |
| close male blood | 0.336852 |
| slightly increased risk | 0.378351 |
| lifetime risk | 0.357498 |
| fatty tissue | 0.342031 |
| average American woman | 0.385569 |
| fatty tissue increases | 0.340815 |
| menopausal hormone therapy | 0.39484 |
| current incidence | 0.346194 |
| women | 0.441907 |
| United States | 0.390167 |
| atypical hyperplasia | 0.338604 |
| individual woman | 0.344493 |
| percent | 0.39834 |
|
| full-term pregnancy | 0.359972 |
| breast cancers | 0.393892 |
| specific ages | 0.341748 |
| dense breasts | 0.348222 |
| breast ducts | 0.38994 |
| breast tissue | 0.419467 |
| National Cancer Institute | 0.363645 |
| progestin menopausal hormone | 0.339022 |
| higher risk | 0.34662 |
| strongest risk factor | 0.391772 |
| breast cancer screening | 0.434635 |
| recent SEER Cancer | 0.368992 |
| breast cancer | 0.950607 |
| dense breast tissue | 0.413692 |
| annual SEER reports | 0.34791 |
| risk factor levels | 0.353691 |
| current incidence rate | 0.341921 |
| slight changes | 0.340621 |
| family history | 0.345271 |
| breast cancer incidence | 0.450564 |
| risk | 0.535827 |
| specific time periods | 0.377721 |
| 10-year age intervals | 0.347265 |
| breast cancer statistics | 0.446445 |
|
CLICK HERE |
| 1728 |
National Cancer Institute |
Html |
en |
End-of-Life Care for People Who Have Cancer |
A fact sheet that answers some of the questions patients, their family members, and caregivers may have about the end of life. |
| family members | 0.618911 |
| family caregivers | 0.218961 |
| advance directives | 0.30098 |
| patients | 0.4187 |
| people | 0.36964 |
| life | 0.365064 |
| caregivers | 0.584429 |
|
| health care team | 0.768547 |
| person | 0.99495 |
| patient | 0.848579 |
| hospice care | 0.29663 |
| Related Resources section | 0.284122 |
| loved ones | 0.266236 |
| cancer | 0.462571 |
|
CLICK HERE |
| 1760 |
National Cancer Institute |
Html |
en |
Obesity and Cancer |
A fact sheet that summarizes the evidence linking overweight and obesity to the risk of various cancers and to cancer survivorship. |
| obesity causes cancer | 0.394065 |
| normal-weight people | 0.279732 |
| observational studies | 0.323456 |
| obesity prevalence | 0.293137 |
| obesity | 0.638496 |
| thyroid cancer risk | 0.290632 |
| obese people | 0.350767 |
| risk factors | 0.298103 |
| multiple myeloma | 0.271306 |
| colorectal cancer | 0.326707 |
| ovarian cancer | 0.293192 |
| body mass index | 0.723663 |
| prostate cancer risk | 0.293391 |
| postmenopausal breast cancer | 0.29585 |
| weight loss | 0.380764 |
| endometrial cancer increases | 0.279353 |
| cancer incidence data | 0.260252 |
| different cancer risk | 0.325913 |
| breast cancer survivors | 0.303032 |
| kidney cancer | 0.323356 |
| endometrial cancer | 0.299756 |
| invasive breast cancer | 0.260923 |
| menopausal hormone therapy | 0.326286 |
| women | 0.298824 |
| gallbladder cancer | 0.347557 |
|
| United States | 0.307003 |
| weight gain | 0.259995 |
| male breast cancer | 0.288797 |
| breast cancer diagnosis | 0.278716 |
| pancreatic cancer | 0.309076 |
| different cancer types | 0.265661 |
| LeRoith D. Obesity | 0.262512 |
| National Cancer Institute | 0.329185 |
| extremely obese women | 0.271426 |
| renal cell cancer | 0.355343 |
| increase cancer risk | 0.312393 |
| breast cancer risk | 0.439989 |
| breast cancer | 0.64758 |
| C. Gallbladder cancer | 0.256715 |
| cancer survivorship | 0.270564 |
| prostate cancer | 0.294021 |
| Breast Cancer WEight | 0.309447 |
| pancreatic cancer risk | 0.295039 |
| breast cancer pooling | 0.266031 |
| prospective studies | 0.320099 |
| et al | 0.828361 |
| cancer risk | 0.662021 |
| cancer | 0.97959 |
| liver cancer | 0.398322 |
|
CLICK HERE |
| 1787 |
National Cancer Institute |
Html |
es |
Prurito (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del prurito (picazón de la piel) como complicación del cáncer y su tratamiento. Se consideran los abordajes de manejo y tratamiento del prurito. |
| funcionamiento renal | 0.688505 |
| cabo pruebas | 0.675786 |
| PDQ Prurito | 0.877657 |
| siguientes aspectos | 0.726626 |
| Diabetes mellitus | 0.704562 |
| Physician Data Query | 0.887758 |
| distintos tipos | 0.680313 |
| Tide Free | 0.679893 |
| cuidado personal | 0.819492 |
| lÃquidos suavizantes | 0.680081 |
| All Free Clear | 0.98679 |
|
| suficientes lÃquidos | 0.704436 |
| largo plazo | 0.693554 |
| medicamentos corticoesteroideos | 0.689382 |
| toallitas suavizantes | 0.68595 |
| determinada afección | 0.743233 |
| National Cancer Institute | 0.676484 |
| bastantes lÃquidos ayuda | 0.75946 |
| siguientes riesgos | 0.661829 |
| siguientes pruebas | 0.722274 |
| ropa all free | 0.721127 |
| Instituto Nacional | 0.734946 |
|
CLICK HERE |
| 1819 |
National Cancer Institute |
Html |
es |
Tratamiento del tumor de Wilms y otros tumores renales infantiles (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del tumor de Wilms y otros tumores renales infantiles. |
| wilms tumor | 0.821427 |
| wilms tumours | 0.50463 |
| anomalÃas congénitas | 0.435681 |
| gen blm | 0.427775 |
| gen oncoinhibidor | 0.442787 |
| gen oncosupresor h19 | 0.43309 |
| gen drosha | 0.426257 |
| anomalÃas cardÃacas congénitas | 0.422372 |
| Ahmed HU | 0.422578 |
| tumores renales | 0.459976 |
| gen ctr9 | 0.450784 |
| gen cdkn1c | 0.42907 |
| renal tumours | 0.428247 |
| afección gen fenotipo | 0.433197 |
| sÃndrome wagr | 0.961757 |
| gen pax6 | 0.452923 |
| Gen Wilms tumor | 0.633712 |
| cánceres renales | 0.430685 |
| sÃndrome congénito | 0.454197 |
| Wilms Tumor Study | 0.602512 |
| gen insulin growth | 0.431312 |
| complejos génicos | 0.423036 |
| anomalÃas renales | 0.500059 |
| gen nsd1 | 0.428186 |
| Beckwith-Wiedemann padecerán | 0.430165 |
|
| Wilms SÃndrome | 0.573396 |
| gen wt1 | 0.557769 |
| gen fbxw7 | 0.42494 |
| Lancet Oncol | 0.427372 |
| restos nefrógenos | 0.582325 |
| Spring Harbor Laboratory | 0.432622 |
| Cold Spring Harbor | 0.432647 |
| sÃndromes wagr | 0.42334 |
| gen ptch1 | 0.424282 |
| efectos tardÃos | 0.471463 |
| tumor wilms | 0.630299 |
| genes wt1 | 0.422664 |
| dominio iiib | 0.434344 |
| antecedentes familiares | 0.436654 |
| Wilms anaplásico difuso | 0.515326 |
| Wilms esporádico | 0.619115 |
| mutaciones interruptoras | 0.593507 |
| gen wtx | 0.481725 |
| monoparental paterna | 0.424225 |
| primary malignant non-wilms | 0.443665 |
| gen tp53 | 0.452138 |
| cánceres embrionarios.Las mutaciones | 0.471064 |
| insuficiencia renal | 0.449112 |
| células renales | 0.428025 |
|
CLICK HERE |
| 3599 |
National Cancer Institute |
Html |
en |
The RAS Initiative |
NCI established the RAS Initiative to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and to ultimately create effective, new therapies for RAS-related cancers. |
| new therapies | 0.393067 |
| RAS | 0.99043 |
| RAS family | 0.739708 |
| long way | 0.387894 |
| oncogenic RAS | 0.6688 |
| primary focus | 0.382845 |
| RAS problem | 0.663793 |
| industry | 0.314692 |
| videos | 0.313651 |
| mouse retroviruses | 0.388906 |
| lab | 0.314136 |
| percent | 0.362189 |
| online forum RAS | 0.726513 |
| RAS reagents | 0.661904 |
| Douglas R. Lowy | 0.440325 |
| RAS genes | 0.803577 |
| Varmus’s vision | 0.381489 |
| RAS hub | 0.667188 |
| entire field | 0.379292 |
| mutations | 0.318554 |
| RAS oncogenes | 0.710337 |
| proteins | 0.316387 |
| Dear Colleagues | 0.397967 |
| National Cancer Institute | 0.440589 |
|
| pancreatic cancers | 0.432526 |
| NCI director | 0.401396 |
| RAS-related cancers | 0.425588 |
| events | 0.31366 |
| group | 0.314948 |
| innovative approaches | 0.393563 |
| goal | 0.328772 |
| biology | 0.314898 |
| academic researchers | 0.385896 |
| RAS Central | 0.733488 |
| virtual network | 0.380109 |
| headway | 0.320561 |
| Dr. Harold Varmus | 0.45561 |
| blog posts | 0.37846 |
| ras initiative | 0.905093 |
| mutant forms | 0.396413 |
| scientists | 0.313674 |
| useful tools | 0.379773 |
| human cancers | 0.42887 |
| fascinating problem | 0.378178 |
| colorectal cancers | 0.432751 |
| concerted effort | 0.392419 |
| time | 0.314762 |
|
CLICK HERE |
| 3768 |
National Cancer Institute |
Html |
en |
NCI Research Specialist Award (R50) |
Award enables scientists to pursue stable research careers within an existing cancer research program, but not serve as independent investigators. Letter of Intent due: January 2, 2017 Application due: February 2, 2017 |
| Research Specialist Award | 0.988915 |
| core-based scientists | 0.581471 |
| grant applications | 0.550206 |
| stable research career | 0.730099 |
| NCI-funded cancer research | 0.716667 |
| PM local time | 0.654064 |
| Funding Opportunity Announcements | 0.676968 |
| context | 0.428705 |
| FOA | 0.51866 |
| laboratory-based scientists | 0.56909 |
| sufficient autonomy | 0.601601 |
| grants | 0.427207 |
| cancer research program | 0.718023 |
| development | 0.427246 |
|
| data scientists | 0.569495 |
| researchers | 0.4266 |
| biomedical research enterprise. | 0.720253 |
| Intent | 0.437384 |
| R50 | 0.455052 |
| opportunities | 0.427151 |
| exceptional scientists | 0.586489 |
| applicant organization | 0.552188 |
| Principal Investigators | 0.571254 |
| core facility managers | 0.705581 |
| NCI Research Specialist | 0.740871 |
| career continuity | 0.565048 |
| FOAs | 0.534084 |
| independent investigators. | 0.567464 |
|
CLICK HERE |
| 15636 |
National Cancer Institute |
Html |
null |
Step 6: Post-Award Administration |
Information on numerous requirements that must be met in order to to be in compliance with NIH policy after receiving an award. This includes implementing monitoring systems and keeping financial and programmatic records. |
|
|
CLICK HERE |
| 16254 |
National Cancer Institute |
Html |
es |
Genómica del cáncer |
La investigación de fundamentos genéticos del cáncer ha mejorado nuestro entendimiento de la biología del cáncer y ha conducido a nuevos métodos de diagnosticar y tratar la enfermedad. |
| colores vibrantes | 0.499759 |
| programas de investigación | 0.654055 |
| posibles genes | 0.505721 |
| próxima generación | 0.497158 |
| prácticas de participación | 0.488897 |
| cambios genómicos que | 0.533603 |
| NCI al hacerlos | 0.685799 |
| gen braf | 0.523508 |
| cáncer y programas | 0.967985 |
| proteÃnas. el nci | 0.703749 |
| gen her2 | 0.525613 |
| investigadores representaciones | 0.514115 |
| facilidad de acceso | 0.490645 |
| alta calidad | 0.874691 |
| lÃnea germinal y exposiciones | 0.549891 |
|
| el instituto nacional | 0.489007 |
| cuáles tratamientos | 0.520412 |
| pequeño porcentaje | 0.500295 |
| Genoma Humano | 0.547332 |
| pacientes correctos | 0.574878 |
| tratamientos en investigación | 0.520771 |
| genes candidatos | 0.501572 |
| tratamientos correctos | 0.52447 |
| Estudios ClÃnicos del NCI | 0.817174 |
| determinada terapia | 0.501736 |
| rasgos genómicos y el | 0.775836 |
| mutaciones impulsoras | 0.525134 |
| la investigación aplicable | 0.503499 |
| datos estén | 0.521046 |
|
CLICK HERE |